AI Engines For more Details: Perplexity Kagi Labs You
Allergic Rhinitis: Diphenylpyraline hydrochloride is used to relieve symptoms of allergic rhinitis, including sneezing, itching, runny or congested nose, and nasal congestion. By blocking the effects of histamine, diphenylpyraline helps alleviate these symptoms and improve quality of life in individuals with allergic rhinitis.
Allergic Conjunctivitis: Diphenylpyraline hydrochloride can also be used to relieve symptoms of allergic conjunctivitis, such as redness, itching, tearing, and swelling of the eyes. It is often used in combination with other medications, such as topical antihistamine eye drops or mast cell stabilizers, for more effective management of eye allergies.
Allergic Skin Reactions: Diphenylpyraline hydrochloride may be prescribed to relieve itching and other symptoms associated with allergic skin reactions, such as urticaria (hives) or eczema. It helps reduce itching and discomfort by blocking histamine receptors in the skin.
Motion Sickness: In addition to its antihistamine effects, diphenylpyraline hydrochloride also has mild sedative properties, which may make it useful in the prevention and treatment of motion sickness. By exerting a calming effect on the central nervous system, diphenylpyraline can help reduce symptoms such as nausea, vomiting, and dizziness associated with motion sickness.
Pruritus: Diphenylpyraline hydrochloride may be used to relieve pruritus (itching) associated with various conditions, such as allergic reactions, insect bites, or dermatitis. Its antihistamine properties help alleviate itching by blocking histamine-mediated itch signals in the skin.
Anaphylaxis: In some cases, diphenylpyraline hydrochloride may be used as part of the treatment regimen for anaphylaxis, a severe and potentially life-threatening allergic reaction. It can help relieve symptoms such as itching, hives, and nasal congestion, although it is not a first-line treatment for anaphylaxis, and more immediate interventions such as epinephrine administration are typically required.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | -0.3 | |
| ADHD | 2.2 | 0.3 | 6.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 2.2 | 2 | 0.1 |
| Allergies | 3.7 | 1.8 | 1.06 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 4.2 | 3.6 | 0.17 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 1.2 | 0.75 |
| Ankylosing spondylitis | 3 | 0.9 | 2.33 |
| Anorexia Nervosa | 1 | 1.2 | -0.2 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.9 | |
| Asthma | 3.3 | 2.1 | 0.57 |
| Atherosclerosis | 2.1 | 0.3 | 6 |
| Atrial fibrillation | 2.2 | 2.2 | 0 |
| Autism | 5.4 | 5.9 | -0.09 |
| Autoimmune Disease | 1.2 | 0.3 | 3 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.3 | 2.3 | |
| Bipolar Disorder | 1.6 | 0.6 | 1.67 |
| Brain Trauma | 0.9 | 0.6 | 0.5 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.6 | 1.3 | -1.17 |
| Carcinoma | 3.3 | 1.3 | 1.54 |
| Celiac Disease | 2.4 | 1.8 | 0.33 |
| Cerebral Palsy | 1.4 | 0.3 | 3.67 |
| Chronic Fatigue Syndrome | 3.1 | 2.5 | 0.24 |
| Chronic Kidney Disease | 3.1 | 1.2 | 1.58 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 0.9 | 1.56 |
| Chronic Urticaria (Hives) | 1.8 | 0.9 | 1 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 0.3 | 5.33 |
| Cognitive Function | 1.6 | 0.6 | 1.67 |
| Colorectal Cancer | 6.6 | 2 | 2.3 |
| Constipation | 1.5 | 1.5 | |
| Coronary artery disease | 2.4 | 1.5 | 0.6 |
| COVID-19 | 5.4 | 5.7 | -0.06 |
| Crohn's Disease | 6.2 | 3.4 | 0.82 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 0.7 | 0.71 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.4 | 0.6 | 3 |
| Denture Wearers Oral Shifts | 1.6 | 1.6 | |
| Depression | 6.9 | 5.1 | 0.35 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.8 | 1.7 | 0.06 |
| Endometriosis | 2.5 | 0.9 | 1.78 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.3 | 1.9 | 0.74 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 1 | 0.9 | 0.11 |
| Functional constipation / chronic idiopathic constipation | 3.6 | 2 | 0.8 |
| gallstone disease (gsd) | 2.6 | 0.9 | 1.89 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 0.3 | 6 |
| Generalized anxiety disorder | 3 | 1.3 | 1.31 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.3 | 4 |
| Graves' disease | 1.6 | 1.4 | 0.14 |
| Gulf War Syndrome | 0.3 | 1.5 | -4 |
| Halitosis | 1.7 | 0.3 | 4.67 |
| Hashimoto's thyroiditis | 1.8 | 0.9 | 1 |
| Heart Failure | 3.1 | 1.2 | 1.58 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.6 | 0.3 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | 0 |
| hyperglycemia | 2.5 | 1.9 | 0.32 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 3 | 1.8 | 0.67 |
| Hypothyroidism | 0.3 | 0.6 | -1 |
| Hypoxia | 2.5 | 0.3 | 7.33 |
| IgA nephropathy (IgAN) | 1.6 | 1.3 | 0.23 |
| Inflammatory Bowel Disease | 6.5 | 4.7 | 0.38 |
| Insomnia | 1.5 | 2 | -0.33 |
| Intelligence | 1.2 | 1.2 | |
| Intracranial aneurysms | 1 | 0.3 | 2.33 |
| Irritable Bowel Syndrome | 5.4 | 3.6 | 0.5 |
| ischemic stroke | 2.4 | 1.2 | 1 |
| Liver Cirrhosis | 5 | 3.5 | 0.43 |
| Long COVID | 5.2 | 2.6 | 1 |
| Lung Cancer | 1.2 | 0.6 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.3 | 4 |
| ME/CFS with IBS | 0.3 | 0.6 | -1 |
| ME/CFS without IBS | 1 | 0.7 | 0.43 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.3 | 1 |
| Metabolic Syndrome | 5.1 | 4.7 | 0.09 |
| Mood Disorders | 6.4 | 4.8 | 0.33 |
| multiple chemical sensitivity [MCS] | 1.5 | 1.5 | |
| Multiple Sclerosis | 4.9 | 2.4 | 1.04 |
| Multiple system atrophy (MSA) | 1 | 0.3 | 2.33 |
| myasthenia gravis | 0.9 | 0.9 | |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.9 | 1 | -0.11 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.3 | 2.3 | 0 |
| NonCeliac Gluten Sensitivity | 1.7 | 0.6 | 1.83 |
| Obesity | 6 | 6.1 | -0.02 |
| obsessive-compulsive disorder | 3.8 | 2 | 0.9 |
| Osteoarthritis | 1.8 | 1.1 | 0.64 |
| Osteoporosis | 1.5 | 1.1 | 0.36 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 5.6 | 3.9 | 0.44 |
| Polycystic ovary syndrome | 3.6 | 1.1 | 2.27 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.6 | 0.4 | 0.5 |
| primary biliary cholangitis | 0.6 | 1.1 | -0.83 |
| Primary sclerosing cholangitis | 1.9 | 0.9 | 1.11 |
| Psoriasis | 2.3 | 2 | 0.15 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 2.4 | 0.67 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 3.8 | 1.6 | 1.37 |
| scoliosis | 0.6 | 0.6 | |
| Sjögren syndrome | 1.8 | 1.7 | 0.06 |
| Sleep Apnea | 0.6 | 0.6 | 0 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.8 | 0.2 | 8 |
| Stress / posttraumatic stress disorder | 2.2 | 2 | 0.1 |
| Systemic Lupus Erythematosus | 3.1 | 0.9 | 2.44 |
| Tic Disorder | 0.9 | 0.6 | 0.5 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 3 | 2.2 | 0.36 |
| Type 2 Diabetes | 6.3 | 5.1 | 0.24 |
| Ulcerative colitis | 4.3 | 3.1 | 0.39 |
| Unhealthy Ageing | 3.4 | 1.6 | 1.13 |
| Vitiligo | 1.6 | 1 | 0.6 |
